Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03084640 · ClinicalTrials.gov registry record · Phase 1
Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma
A Phase 1 study of Malignant Melanoma, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 4
- Study locations
NCT03084640: Completed Phase 1 study of Malignant Melanoma, sponsored by Regeneron Pharmaceuticals.
NCT03084640 is a Phase 1 study of Malignant Melanoma that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 30 participants, below the 182-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (84% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03084640, a Phase 1 study of Malignant Melanoma, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 4
- Study locations
Study Summary
CMP-001-002 is a Phase 1b study of CMP-001 administered to participants with advanced melanoma who are either receiving pembrolizumab, or who have previously received an anti-programmed cell death protein 1 (anti-PD-1)/programmed death-ligand 1 (PD-L1) therapy for advanced melanoma, and who have not responded (that is, immunotherapy resistant). This study will be conducted in two parts: Part 1 will consist of a Dose Escalation Phase and a Dose Expansion Phase * Dose Escalation Phase will be conducted to assess and identify a recommended phase 2 dose (RP2D) of CMP-001 for subcutaneous (SC) administration * The Dose Expansion Phase is intended to further characterize the safety, pharmacodynamics, and preliminary evidence of antitumor activity of the RP2D of CMP-001 administered SC in combination with pembrolizumab Part 2 will assess the safety and preliminary evidence of antitumor activity of CMP-001, administered both SC and intratumoral (IT) when given in combination with pembrolizumab. Participants will continue treatment with CMP-001 in combination with pembrolizumab as long as they do not experience unacceptable toxicities and when continued treatment, is in the participant's best interest according to the Investigator.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG CMP-001
Study Locations (4)
California
- University of California, Los Angeles - Los Angeles
Colorado
- University of Colorado - Aurora
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Pennsylvania
- University of Pittsburgh Medical Center - Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-05-04 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 1 |
What the finished NCT03084640 record still lists
NCT03084640 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 182-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03084640 reports a single indexed study location in California, Colorado, Iowa.
Frequently Asked Questions
What is clinical trial NCT03084640 about?
NCT03084640 is a clinical study titled "Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma". CMP-001-002 is a Phase 1b study of CMP-001 administered to participants with advanced melanoma who are either receiving pembrolizumab, or who have previously received an anti-programmed cell death protein 1 (anti-PD-1)/programmed death-ligand 1 (PD-L1) therapy for advanced melanoma, and who have not...
What is the current status of trial NCT03084640?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-05-04. Estimated completion is 2021-09-30.
What conditions does trial NCT03084640 study?
This clinical trial studies the following conditions: Malignant Melanoma.
What interventions are being tested in trial NCT03084640?
The interventions under investigation include: Pembrolizumab (DRUG), CMP-001 (DRUG).
Who is sponsoring clinical trial NCT03084640?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03084640 being conducted?
This trial has 4 study locations across California, Colorado, Iowa, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03084640's enrollment target sits among peer trials
30 19th of 28 higher than 10 of 28 other Malignant Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
-
Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC
RECRUITING · Phase 1
-
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
RECRUITING · Phase 1
-
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RECRUITING · Phase 1
-
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI